Table 2.
Associations of left ventricular mass index quartiles with incident heart failure in the Chronic Renal Insufficiency Cohort participants without heart failure
| LVMI Q (g/m2.7) | N (Events) | N (Participants) | Rate (Events/1000 person-yr) | HR (95% CI) | ||
|---|---|---|---|---|---|---|
| Model 1 | Model 2 | Model 3 | ||||
| All | ||||||
| Q1 (<41.3) | 11 | 641 | 2.8 | Reference | Reference | Reference |
| Q2 (41.3 to <48.5) | 29 | 643 | 8.0 | 1.82 (0.9 to 3.7) | 1.73 (0.85 to 3.52) | 1.55 (0.76 to 3.17) |
| Q3 (48.5 to <57.5) | 55 | 642 | 16.7 | 3.19 (1.62 to 6.3) | 3.05 (1.54 to 6.04) | 2.71 (1.36 to 5.4) |
| Q4 (≥57.5) | 119 | 641 | 43.2 | 5.23 (2.63 to 10.41) | 4.89 (2.45 to 9.75) | 3.96 (1.96 to 8.02) |
| Linear trend P value | <0.001 | <0.001 | <0.001 | |||
| Men | ||||||
| Q1 (<41.7) | 5 | 345 | 2.4 | Reference | Reference | Reference |
| Q2 (41.7 to <48.8) | 17 | 344 | 9.1 | 2.25 (0.81 to 6.23) | 2.21 (0.8 to 6.14) | 1.89 (0.67 to 5.32) |
| Q3 (48.8 to <57.4) | 33 | 345 | 19.2 | 3.77 (1.42 to 10.01) | 3.57 (1.34 to 9.49) | 3.06 (1.14 to 8.23) |
| Q4 (≥57.4) | 59 | 344 | 42.2 | 4.61 (1.7 to 12.5) | 4.38 (1.61 to 11.89) | 3.52 (1.28 to 9.71) |
| Linear trend P value | <0.01 | <0.01 | 0.05 | |||
| Women | ||||||
| Q1 (<40.8) | 6 | 297 | 3.3 | Reference | Reference | Reference |
| Q2 (40.8 to <47.9) | 12 | 297 | 6.9 | 1.43 (0.52 to 3.9) | 1.23 (0.45 to 3.39) | 1.2 (0.43 to 3.35) |
| Q3 (47.9 to <57.7) | 23 | 298 | 14.6 | 2.91 (1.11 to 7.65) | 2.8 (1.06 to 7.41) | 2.64 (0.97 to 7.19) |
| Q4 (≥57.7) | 59 | 297 | 43.7 | 6.41 (2.41 to 17.04) | 5.27 (1.97 to 14.12) | 4.96 (1.78 to 13.81) |
| Linear trend P value | <0.001 | <0.001 | <0.001 | |||
Model 1: age, race, study site, diabetes, cardiovascular disease, tobacco, alcohol use, log(24-hour proteinuria), eGFR (Chronic Renal Insufficiency Cohort equation), systolic BP, diastolic BP, body mass index, LDL, HDL, aldosterone antagonists, angiotensin–converting enzyme inhibitors, angiotensin receptor blockers, diuretics, β-blockers, phosphate, and hemoglobin. Model 2: model 1 plus log(parathyroid hormone), log(fibroblast growth factor-23), aspirin, and statin. Model 3: model 2 plus log(B–type natriuretic peptide) and log(high–sensitivity troponin T). LVMI, left ventricular mass index; Q, quartile; HR, hazard ratio; 95% CI, 95% confidence interval.